[Survival analysis for high-grade glioma patients who received comprehensive treatment].
To analyze the curative effect and prognostic factors for comprehensive therapy in patients with high-grade glioma. Methods: Patients with high-grade glioma (WHO grade III, grade IV) were chosen from July 2008 to May 2016 in the Hunan Cancer Hospital, and a retrospective analysis was performed in 64 patients with complete follow-up data. Results: The follow-up time was 3-111 (median 29.5) months, the median overall survival time was 36.00 (95% CI 22.85 to 49.16) months, the median progression-free survival time (PFS) was 21.00 (95% CI 9.72 to 32.28) months. The 1-year, 2-year, 3-year and 5-year survival rates of high-grade glioma patients were 87.50%, 56.25%, 40.63% and 17.19%, respectively. The univariate analysis of Log-Rank test and the Cox regression model analysis showed that the prognostic factors related to the prognosis of high-grade glioma patients were pathological grade, resection degree, and concurrent chemo-radiotherapy (P<0.05). Conclusion: The overall survival time, progression-free survival time and the 5-year survival rate of patients with high-grade glioma after comprehensive treatment is partially improved. The factors relevant to the prognosis of patients with high-grade glioma are pathological grade, resection degree, and concurrent chemo-radiotherapy, indicating that the glioma patients (WHO grade III) received total resection of the tumor and concurrent chemo-radiotherapy have better clinical effect.